Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
The U.S. Supreme Court today put an end to a patent infringement lawsuit between Baxter and Fresenius when it declined to review the case.
The Supremes’ decision to deny certiorari in Baxter et al v. Fresenius et al means last year’s reversal of Baxter’s win over dialysis device rival Fresenius will stand. Read more
C.R. Bard won a date for an FDA panel review next for its Lutonix drug-eluting balloon in treating peripheral artery disease, ahead of its bid for approval to put the device on the U.S. market.
The FDA’s Circulatory System Devices Panel is slated to meet June 12 to review Bard’s pre-market approval application for the Lutonix balloon, which is coated with the anti-restenosis drug paclitaxel. Read more
Medtronic agreed to pay $750 million to Edwards Lifesciences to put to rest their international patent infringement war over transcatheter aortic valve implants and other technologies.
The deal includes a provision that will see Medtronic pay royalties through April 2022 of at least $40 million annually. It also puts to rest all other pending litigation between the medical device companies. Neither company admitted to any infringement as part of the settlement. Read more